Orion Corporation: Major Shareholder Announcement - BlackRock, Inc. Disclosure

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 20 January 2026 at 08.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds, and the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 16 January 2026 above five (5) per cent of Orion Corporation’s total shares. Total positions of BlackRock, Inc. and its funds subject to notification: % of shares and voting rights (total of point A)% of shares and voting rights through financial instruments (total of point B)Total of both in % (points A + B)Total number of shares and voting rights of issuerResulting situation on the date on which threshold was crossed or reached5.00% shares Below 5% voting rights0.00% shares Below 5% voting rights5.00% shares Below 5% voting rights141,134,278 shares 741,296,626 voting rightsPosition of previous notification (if applicable)Below 5% shares Below 5% voting rightsBelow 5% shares Below 5% voting rightsBelow 5% shares Below 5% voting rights Notified details of the resulting situation on the date on which the threshold was crossed: Point A: Shares and voting rights: Class/type of shares ISIN codeNumber of shares and voting rights% of shares and voting rightsDirect (SMA 9:5)Indirect (SMA 9:6 and 9:7)Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)FI00090143777,060,661 shares Below 5% voting rights5.00% shares Below 5% voting rightsPOINT A SUBTOTAL7,060,661 shares Below 5% voting rights5.00% shares Below 5% voting rights Point B: Financial instruments according to SMA 9:6a: Type of financial instrumentExpiration dateExercise / Conversion PeriodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rightsAmerican Depositary Receipt (US68628Y1047)N/AN/APhysical192 shares Below 5% voting rights0.00% shares Below 5% voting rightsPOINT B SUBTOTAL192 shares Below 5% voting rights0.00% shares Below 5% voting rights Orion Corporation Liisa Hurme President and CEOMikko Kemppainen General Counsel Contact person: Tuukka Hirvonen, Investor Relations, Orion Corporation tel. +358 10 426 2721 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland www.orionpharma.com Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.